Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

En 48-månaders studie för att utvärdera långtidseffektiviteten av Elocta på ledhälsa (A-MORE)

18 september 2026 uppdaterad av: Swedish Orphan Biovitrum

En 48-månaders, multi-center, observationsstudie för att utvärdera den långsiktiga effektiviteten av Elocta på ledhälsa

This is a 48-month observational, prospective, multicentre study. The overall aim of the study is to evaluate the long-term effectiveness of Elocta treatment on joint health in patients treated prophylactically with Elocta in a real-world setting.

Studieöversikt

Status

Avslutad

Betingelser

Intervention / Behandling

Detaljerad beskrivning

Haemophilia A is a rare genetic disorder estimated to occur in one out of 10,000 live births, characterized by a deficiency in coagulation factor VIII causing impaired haemostasis and prolonged bleeding episodes. Moderate haemophilia, defined as < 5%, and severe haemophilia, defined as < 1% of normal factor VIII activity result in frequent and spontaneous bleeds into muscles and joints, commonly the elbows, knees, and ankles. Bleeding into joints can cause acute pain and swelling and can result in reduced joint range of motion, long-term cartilage damage and debilitating haemophilic arthropathy. Early use of prophylaxis with factor VIII replacement is recommended following diagnosis of haemophilia A to maintain joint health and prevent joint destruction. However, despite the use of prophylaxis many patients still experience joint bleeds which may lead to joint deterioration over time. The risk of joint bleeds increases with the amount of time spent below certain FVIII trough levels, e.g. 1, 3 or 5 IU/dL. Thus, there is probably a relation between the intensity of the prophylactic treatment regimen and joint health. Elocta is an extended half-life rFVIII product (EHL rFVIII), with a slower clearance as compared to conventional FVIII products. Treatment with Elocta will therefore provide the treater with a greater flexibility for individualizing prophylaxis as compared to conventional FVIII. Higher trough levels can be reached with Elocta without increasing factor usage or injection frequency. The treater can instead choose to reduce the injection frequency or the factor consumption without lowering trough levels.

Patients may limit their physical activities due to fear of bleeding if they are unaware of their current FVIII level. Patient apps and wearables are now available which allow patients to view their predicted FVIII levels, and capture health-related data (such as bleedings, pain, well-being, physical activity levels etc.). This data can be shared with the treating physician supporting the planning to individualize the patient's factor treatment based on current lifestyle, health status and physical activity levels. Florio, a certified medical device used as part of routine clinical practice, is such an app, and the data output and patient feedback on their activity levels and sense of protection while using Florio will be analysed as exploratory objectives in this study.

The main purpose of this study is to evaluate the effectiveness of Elocta on joint health over a long observation period (48 months). The study will also explore the influence on long term joint health of different Elocta prophylaxis regimens leading to different trough levels and if the extent of patients' physical activity levels can be associated with predicted FVIII levels.

Studietyp

Observationell

Inskrivning (Faktisk)

427

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

      • Tallinn, Estland
        • Lastehaigla, Tallinn (Tallinn Children´s Hospital)
      • Tallinn, Estland
        • The North Estonia Medical Centre Hematoloogiakeskus, Regionalhaigla
      • Helsinki, Finland
        • Helsinki University Central Hospital, New Children Hospital
      • Turku, Finland
        • Turku University Central Hospital, Paediatric and adolescent haematology and oncology clinic
      • Thessaloniki, Grekland
        • Ippokrateio Hospital Thessaloniki (adult department)
      • Thessaloniki, Grekland
        • Ippokrateio Hospital Thessaloniki (pediatric department)
      • Bari, Italien
        • University of Bari Aldo Moro (Centro Emofilia Policlinico - Pediatria U.O.)
      • Cesena, Italien
        • AUSL Romagna Centro Emofilia U.O.C., Medicina Trasfusionale Dipartimento Patologia, Clinica Ospedale M. Bufalini
      • Genova, Italien
        • Giannina Gaslini Institute
      • Milan, Italien
        • Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico
      • Parma, Italien
        • University Hospital of Parma, AOUP, Haemophilia Center
      • Rome, Italien
        • Uo Malattie Emorragiche e Trombotiche Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Universitá Catolica del Sacro Coure
      • Torino, Italien
        • Azienda Ospedaliera Città della Salute e della Scienza di Torino Regina Margherita
      • Groningen, Nederländerna
        • University Medical Center Groningen/UMCG
      • Muscat, Oman
        • The Royal Hospital
      • Riyadh, Saudiarabien
        • Dr Suliman Al Habib Hospital Riyadh
      • Riyadh, Saudiarabien
        • King Faisal Specialised Hospital, KFSH Riyadh, Children
      • Riyadh, Saudiarabien
        • King Faisal Specialist Hospital KFSH, Adults
      • Riyadh, Saudiarabien
        • Riyadh Military Hospital (P.S.M.C)
      • Bern, Schweiz
        • Universitätsklinik für Hämatologie und Hämatologisches Zentrallabor Inselspital
      • Lausanne, Schweiz
        • Service et Laboratoire central d'hématologie, Adults
      • Sankt Gallen, Schweiz
        • Zentrum für Labormedizin
      • Zurich, Schweiz
        • Universitätsspital Zürich Klinik für Medizinische Onkologie und Hämatologie
      • Ljubljana, Slovenien
        • University Medical Centre Ljubljana Division of Paediatrics
      • Barcelona, Spanien
        • Sant Johan De Deu
      • Barcelona, Spanien
        • Hospital de la Santa Creu i Sant Pau
      • Barcelona, Spanien
        • Hospital Vall d'Hebron
      • Cruces, Spanien
        • Hospital Universitario Cruces
      • Donostia / San Sebastian, Spanien
        • Hospital Universitario Donostia
      • Murcia, Spanien
        • Hospital Virgen de la Arrixaca
      • Málaga, Spanien
        • Hospital Universitario Carlos Haya
      • Navarro, Spanien
        • Complejo Hospitalario de Navarra
      • Oviedo, Spanien
        • Hospital Universitario Central de Asturias (HUCA)
      • Palma de Mallorca, Spanien
        • Hospital Universitario Son Espases
      • Seville, Spanien
        • Hospital Universitario Virgen del Rocío
      • Vigo, Spanien
        • Hospital Alvaro Cunqueiro
      • Canterbury, Storbritannien
        • East Kent Hospitals University NHS Foundation Trust, Kent Haemophilia and Thrombosis Centre, Kent and Canterbury Hospital
      • London, Storbritannien
        • Great Ormond Street Hospital, Royal London Hospital for Integrated Medicine
      • Gothenburg, Sverige
        • Hematologimottagning Sahlgrenska
      • Malmö, Sverige
        • Department of Haematology, Oncology and Radiation Physics, Skåne University Hospital Malmö
      • Brno, Tjeckien
        • University Hospital Brno
      • Ostrava, Tjeckien
        • University Hospital Ostrava
      • Prague, Tjeckien
        • Dept. of Pediatric Haematology and Oncology, University Hospital Motol
      • Berlin, Tyskland
        • Charité-Universitätsmedizin Berlin Campus Virchow Klinikum
      • Bonn, Tyskland
        • Universitätsklinikum Bonn AöR, Institut für Experimentelle Hämatologie und Transfusionsmedizin
      • Frankfurt, Tyskland
        • Hämostaseologie/Hämophiliezentrum, Medizinische Klinik 2 Institut für Transfusionsmedizin, Universitätsklinikum
      • Frankfurt, Tyskland
        • Universitätsklinikum Frankfurt - Klinik für Kinder- und Jugendmedizin
      • Hamburg, Tyskland
        • Universitätsklinikum Hamburg-Eppendorf (UKE)
      • Hanover, Tyskland
        • Medizinische Hochschule Hannover
      • Hanover, Tyskland
        • Werlhof-Institut für Hämostaseologie GmbH
      • Heidelberg, Tyskland
        • SRH-Klinikum Heidelberg
      • Mörfelden-Walldorf, Tyskland
        • HZRM Hämöphilie Zentrum Rhein Main
      • München, Tyskland
        • Kinderklinik und Kinderpoliklinik im Dr. von Haunerschen Kinderspital am Universitätsklinikum München

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

  • Barn
  • Vuxen
  • Äldre vuxen

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Testmetod

Icke-sannolikhetsprov

Studera befolkning

Patients diagnosed with haemophilia A regardless of severity, of any gender and age, on factor treatment with Elocta according to usual clinical practice.

Beskrivning

Inclusion Criteria:

  • Provided signed and dated informed consent by the patient, or the patient's legally authorized representative(s) for patients under the legal age, before any study-related activities are undertaken. Assent should be obtained from paediatric patients according to local regulations
  • Have a diagnosis of haemophilia A
  • At enrolment on prophylactic treatment with Elocta, independent of participation in the study

Exclusion Criteria:

  • Enrolment in another concurrent clinical interventional study, or intake of an Investigational Medicinal Product (IMP), within three months prior to inclusion in this study
  • Presence of factor VIII antibodies (inhibitors) (≥0.60 Bethesda Unit [BU]/mL) at the latest available inhibitor test

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Observationsmodeller: COHORT
  • Tidsperspektiv: PROSPECTIVE

Kohorter och interventioner

Grupp / Kohort
Intervention / Behandling
Hemophilia A patients

All patients diagnosed with haemophilia A regardless of severity, on factor treatment with Elocta according to usual clinical practice.

Extended half-life factor VIII product

Andra namn:
  • efmoroctocog alfa
  • VÄLJA
  • rFVIIIFc

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Joint health: Target joint development
Tidsram: 48 months

Number of target joints

48 months
Joint health: Target joint resolution
Tidsram: 48 months

Number of resolved target joints

48 months
Joint health: Target joint recurrence
Tidsram: 48 months

Number of recurring target joints

48 months
Joint health: Annualised joint bleeding rate (AJBR) for treated bleeds
Tidsram: 48 months

Number of joint bleeding events per year, for treated bleeds

48 months

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Disease Activity (hypertrophic synovium) and Disease Damage (Cartilage or Bone) scores for elbows, knees and ankles
Tidsram: 48 months

The Haemophilia Early Arthropathy Detection with UltraSound (HEAD-US) protocol will be used. The total score represents the sum of item scores for abnormalities detected. Its values range from 0 (minimum) to 8 (maximum). A higher score indicates a worse outcome.

48 months
Global Gait Score, and/or joint score items for elbows, knees and ankles.
Tidsram: 48 months

The Haemophilia Joint Health Score (HJHS) system will be used. Global Gait Score, and/or Joint score items (swelling, duration of swelling, muscle atrophy, axial alignment, crepitus on motion, flexion loss, instability, extension loss, joint pain, strength, gait) for elbows, knees and ankles.

The minimum score per joint is 0, the maximum score is 20. The overall total joint score (range 0-120) is the sum of the 6 six index joint (elbows, knees and ankles) scores. A higher score indicates a worse outcome.

48 months
Joint and physical evaluation for elbows, knees and ankles.
Tidsram: 48 months

The WFH Physical Examination Score (AKA Gilbert Score) will be used. Joint evaluation (pain, bleeding, physical examination and radiologic evaluation) and physical evaluation (swelling, muscle atrophy, axial deformity, crepitus on motion, range of motion, flexion contracture, and instability). A higher score indicates a worse outcome.

48 months

Andra resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Effectiveness of Elocta: Annualised bleeding rate (ABR) for treated bleeds
Tidsram: 48 months

Number of bleeding events per year, for treated bleeds

48 months
Effectiveness of Elocta: Annualised bleeding rate (ABR) for all bleeds
Tidsram: 48 months

Number of bleeding events per year, for all bleeds

48 months
Effectiveness of Elocta: Occurrence of zero (0) joint bleeds
Tidsram: 48 months

Percentage (%) of study population with zero (0) joint bleeds

48 months
Effectiveness of Elocta: Work productivity and impairment
Tidsram: 48 months

Assessed by WPAI-SHP questionnaire

48 months
Effectiveness of Elocta: Quality of Life
Tidsram: 48 months

Assessed by Haemo-QoL/Haem-A-QoL questionnaire

48 months
Effectiveness of Elocta: Physical activity level
Tidsram: 48 months

Assessed by the Saltin-Grimby scale

48 months
Effectiveness of Elocta: Quality of Life
Tidsram: 48 months

Assessed by EQ-5D-5L/EQ-5D-Y questionnaire

48 months
Effectiveness of Elocta: Severity of joint health
Tidsram: 48 months

Assessed by Patient Global Impression of Severity of Joint Health questionnaire

48 months
Effectiveness of Elocta: FVIII plasma levels
Tidsram: 48 months

Percentage (%) of FVIII plasma level

48 months
Effectiveness of Elocta: Usage of pain and anti-inflammatory medication
Tidsram: 48 months

Assessed by medication dose

48 months
Effectiveness of Elocta: Usage of pain and anti-inflammatory medication
Tidsram: 48 months

Assessed by total number of exposure days per medication

48 months
Usage of Elocta: Annualised injection frequency per subject
Tidsram: 48 months

Assessed by prescription

48 months
Usage of Elocta: Annualised factor consumption per subject
Tidsram: 48 months

Assessed by prescription [IU/kg]

48 months
Usage of Elocta: Adherence
Tidsram: 48 months

Investigator assessed (Percentage (%))

48 months
Exploratory Objective
Tidsram: 48 months

Influence of different Elocta prophylaxis regimens on long term joint health

48 months
Exploratory Objective: Impact of florio HAEMO on patients' sense of protection and their activity level
Tidsram: 48 months

Results from questionnaire on impact of florio HAEMO tools on patients' sense of protection and their activity level

48 months
Exploratory Objective: Explore adherence to prescribed treatment regimen
Tidsram: 48 months

florio HAEMO captured treatment adherence scores

48 months
Exploratory Objective: Explore relationship between predicted FVIII levels and physical activity
Tidsram: 48 months

florio HAEMO captured predicted FVIII levels, florio HAEMO captured physical activity (type, duration, heart rate and steps)

48 months
Exploratory Objective: Explore timing of bleeds in relation to predicted FVIII levels and physical activity
Tidsram: 48 months

florio HAEMO captured bleed data (timing, location, cause, treated/untreated), florio HAEMO captured injection data (time, dose), florio HAEMO captured predicted FVIII levels

48 months
Exploratory Objective: Explore the use of Florio to characterise pain and well-being
Tidsram: 48 months

florio HAEMO captured pain data (time, location, cause, intensity), florio HAEMO captured well-being data

48 months
Exploratory Objective: Influence of different Elocta prophylaxis regimens on long term joint health
Tidsram: 48 months

Target joint development, resolution and recurrence

48 months
Exploratory Objective: Influence of different Elocta prophylaxis regimens on long term joint health
Tidsram: 48 months

Annualised joint bleeding rate (AJBR) for treated bleeds

48 months
Exploratory Objective: Influence of different Elocta prophylaxis regimens on long term joint health
Tidsram: 48 months

Ultrasound (HEAD-US)

48 months
Exploratory Objective: Influence of different Elocta prophylaxis regimens on long term joint health
Tidsram: 48 months

Clinical joint scoring (HJHS)

48 months
Exploratory Objective: Influence of different Elocta prophylaxis regimens on long term joint health
Tidsram: 48 months

Annualised bleeding rate (ABR) (based on bleeding episodes assessed according to local practice) for all bleeds

48 months
Exploratory Objective: Influence of different Elocta prophylaxis regimens on long term joint health
Tidsram: 48 months

Occurrence of zero (0) joint bleeds

48 months
Exploratory Objective: Influence of different Elocta prophylaxis regimens on long term joint health
Tidsram: 48 months

Quality of Life assessed by Haemo-QoL/Haem-A-QoL

48 months
Exploratory Objective: Influence of different Elocta prophylaxis regimens on long term joint health
Tidsram: 48 months

Physical activity level assessed by the Saltin-Grimby scale

48 months

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Studierektor: Study Physician, Swedish Orphan Biovitrum

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

30 mars 2020

Primärt slutförande (Faktisk)

4 maj 2026

Avslutad studie (Faktisk)

4 maj 2026

Studieregistreringsdatum

Först inskickad

20 februari 2020

Först inskickad som uppfyllde QC-kriterierna

2 mars 2020

Första postat (Faktisk)

3 mars 2020

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

22 september 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

18 september 2026

Senast verifierad

1 september 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera